TNXP (Tonix Pharmaceuticals Holding) Ending Cash Position: $176.62 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TNXP Tonix Pharmaceuticals Holding Corp TNXP
41 GF Score
Price $13.58
GF Value $3.16
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Ending Cash Position?

Tonix Pharmaceuticals Holding TNXP +0.30% 41 Ending Cash Position is $176.62 Mil as of Jun. 2026. GuruFocus rates TNXP with a GF Score™ of 41/100 and a GF Value™ of $3.16 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Tonix Pharmaceuticals Holding's Ending Cash Position for the quarter that ended in Jun. 2026 was $176.62 Mil.

Tonix Pharmaceuticals Holding's quarterly Ending Cash Position declined from Dec. 2025 ($209.81 Mil) to Mar. 2026 ($186.01 Mil) and declined from Mar. 2026 ($186.01 Mil) to Jun. 2026 ($176.62 Mil).

Tonix Pharmaceuticals Holding's annual Ending Cash Position increased from Dec. 2023 ($25.85 Mil) to Dec. 2024 ($99.68 Mil) and increased from Dec. 2024 ($99.68 Mil) to Dec. 2025 ($209.81 Mil).

Tonix Pharmaceuticals Holding Ending Cash Position Related Terms

Tonix Pharmaceuticals Holding Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Tonix Pharmaceuticals Holding's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Ending Cash Position Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 178.90 120.47 25.85 99.68 209.81

Tonix Pharmaceuticals Holding Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 126.24 191.35 209.81 186.01 176.62
TNXP
41GF Score
Tonix Pharmaceuticals Holding Corp TNXP
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonix Pharmaceuticals Holding Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tonix Pharmaceuticals Holding's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=99.68+110.127
=209.81

Tonix Pharmaceuticals Holding's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=186.008+-9.389
=176.62

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $176.62 Mil mean?
Tonix Pharmaceuticals Holding (TNXP) has a Ending Cash Position of $176.62 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tonix Pharmaceuticals Holding and its competitors.
Is Tonix Pharmaceuticals Holding's Ending Cash Position too high?
Tonix Pharmaceuticals Holding's current Ending Cash Position is $176.62 Mil. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Ending Cash Position compare to EQ and ARCT?
Tonix Pharmaceuticals Holding's Ending Cash Position of $176.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tonix Pharmaceuticals Holding and its competitors. Tonix Pharmaceuticals Holding's current Ending Cash Position is $176.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.16, compared to a current price of $13.58 — trading 329.7% above its estimated fair value. The current Ending Cash Position is $176.62 Mil. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Ending Cash Position is $176.62 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $13.58 is trading 329.7% above its estimated GF Value™ of $3.16. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

  • Ending Cash Position: $176.62 Mil
  • GF Value™: $3.16 vs. price of $13.58 (329.7% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonix Pharmaceuticals Holding Business Description

Other Exchanges TPM0:Germany
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
41GF Score

Get the complete analysis for TNXP

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.58
Price
$3.16
GF Value